-
Mashup Score: 0Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study - 6 month(s) ago
Objective To evaluate the safety and efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) in a large North American cohort. Methods Patients with GCA treated with TCZ between January 1, 2010, and May 15, 2020, were retrospectively identified. Kaplan-Meier methods were used to estimate time to TCZ discontinuation and time to first relapse after TCZ discontinuation. Poisson regression models were used to compare annualized relapse rates before, during, and after TCZ use. Age- and sex-adjusted risk factors associated with relapse on and off TCZ and development of adverse events of significant interest (AESIs) were examined using Cox models. Results One hundred fourteen patients (60.5% female) were included with mean (SD) age 70.4 (8.2) years. Median duration from GCA diagnosis to TCZ start was 4.5 months. Median overall duration of TCZ treatment was 2.3 years. Relapse rate prior to TCZ start (0.84 relapses/person-year) was 3-fold reduced while on TCZ (0.28 relapses/person-year; P <
Source: www.jrheum.orgCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Tocilizumab for antibody-mediated rejection treatment in lung transplantation - PubMed - 8 month(s) ago
Tocilizumab (TCZ), an IL-6 inhibitor, has shown promise in the treatment of donor-specific antibodies (DSA) and chronic antibody-mediated rejection (AMR) in renal transplant recipients. However, its use in lung transplantation has not been described. This retrospective case-control study compared AM …
Source: pubmed.ncbi.nlm.nih.govCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Background The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action. Methods Investigator-initiated, randomised, blinded-assessor study. Patients with treatment-naïve early RA with moderate–severe disease activity were…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 7Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients - 10 month(s) ago
Objective To evaluate tocilizumab (TCZ) efficacy in patients with refractory Behçet disease (BD). Methods This is a multicenter study of 30 patients fulfilling the international criteria for BD and treated with TCZ at different European referral centers. The clinical response was evaluated at 6 months from TCZ initiation. Results Ninety percent of patients with BD were refractory or intolerant…
Source: The Journal of RheumatologyCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 5Giant Cell Arteritis Podcasts - 11 month(s) ago
23 May 2023 We’re excited to present a series of engaging and informative giant cell arteritis podcasts that delve into various aspects of rheumatology. In this blog post, we will highlight three episodes that provide valuable insights and information from our Talking Rheumatology Cases, Spotlight, and Research podcasts. Podcast 1: “Non-GCA Headache”…
Source: www.rheumatology.org.ukCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Pharmacokinetics, Immunogenicity Comparable Between Tocilizumab and Potential Biosimilar LZM008 - 1 year(s) ago
Patients receiving tocilizumab and LZM008 showed comparable pharmacokinetic properties after a single intravenous dose.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Pharmacokinetics, Immunogenicity Comparable Between Tocilizumab and Potential Biosimilar LZM008 - 1 year(s) ago
Patients receiving tocilizumab and LZM008 showed comparable pharmacokinetic properties after a single intravenous dose.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Tocilizumab Biosimilar, MSB11456, Demonstrates Similar Pharmacokinetics, Safety Profiles - 1 year(s) ago
A recent study found that the biosimilar MSB11456 showed pharmacokinetic similarity, immunogenicity, and safety profiles comparable to the reference drug, tocilizumab, suggesting that it could be a cost-effective alternative for treating autoimmune disorders.
Source: HCP LiveCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Tocilizumab Biosimilar, MSB11456, Demonstrates Similar Pharmacokinetics, Safety Profiles - 1 year(s) ago
A recent study found that the biosimilar MSB11456 showed pharmacokinetic similarity, immunogenicity, and safety profiles comparable to the reference drug, tocilizumab, suggesting that it could be a cost-effective alternative for treating autoimmune disorders.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0FDA Approves Tocilizumab for COVID-19 in Hospitalized Adults - 1 year(s) ago
The indication makes tocilizumab the first monoclonal antibody to be granted full FDA approval to treat the pandemic virus.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
Research Article Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study 📰 https://t.co/7N2dHPqL2N #giantcellarteritis #tocilizumab #treatment #vasculitis https://t.co/od0nRxB7lS